1-(4-(difluoromethoxy)phenyl)guanidinium nitrate | 1448633-41-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 1-(4-(difluoromethoxy)phenyl)guanidinium nitrate
• CAS: 1448633-41-7
• 化学式: C₈H₉F₂N₃O*HNO₃
• 分子量: 264.189
• InChiKey: VMHXBKOEJHOGND-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.25
• 重原子数：
  18.0
• 可旋转键数：
  3.0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  134.5
• 氢给体数：
  4.0
• 氢受体数：
  4.0

反应信息

• 作为反应物：
  描述：

  1-(4-(difluoromethoxy)phenyl)guanidinium nitrate 、 2-(dimethylaminomethylidene)-5-methylcyclohexane-1,3-dione 在 三乙胺 作用下， 以 乙醇 为溶剂， 以66%的产率得到(rac)-2-((4-(difluoromethoxy)phenyl)amino)-7-methyl-7,8-dihydroquinazolin-5(6H)-one
  参考文献：
  名称：

  Discovery, synthesis, and structure–activity relationships of 2-aminoquinazoline derivatives as a novel class of metabotropic glutamate receptor 5 negative allosteric modulators

  摘要：

  A virtual screening approach using various in silico methodologies led to the discovery of 2-(m-tolylamino)-7,8-dihydroquinazolin-5(6H)-one (1) as a moderately active negative allosteric modulator (NAM) of the metabotropic glutamate receptor subtype 5 (mGluR5) showing high selectivity against the subtype mGluR1. Modifications of the parent compound by rational design yielded a series of highly potent derivatives which will serve as valuable starting points for further hit-to-lead optimization efforts toward a suitable drug candidate for the treatment of L-DOPA induced dyskinesia. (c) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.06.049
• 作为产物：
  描述：

  氰胺 、 4-二氟甲氧基苯胺 在 硝酸 作用下， 以 乙醇 、 水 为溶剂， 反应 12.0h， 以58%的产率得到1-(4-(difluoromethoxy)phenyl)guanidinium nitrate
  参考文献：
  名称：

  Discovery, synthesis, and structure–activity relationships of 2-aminoquinazoline derivatives as a novel class of metabotropic glutamate receptor 5 negative allosteric modulators

  摘要：

  A virtual screening approach using various in silico methodologies led to the discovery of 2-(m-tolylamino)-7,8-dihydroquinazolin-5(6H)-one (1) as a moderately active negative allosteric modulator (NAM) of the metabotropic glutamate receptor subtype 5 (mGluR5) showing high selectivity against the subtype mGluR1. Modifications of the parent compound by rational design yielded a series of highly potent derivatives which will serve as valuable starting points for further hit-to-lead optimization efforts toward a suitable drug candidate for the treatment of L-DOPA induced dyskinesia. (c) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.06.049